Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12700643 | 0.77 | CSNK2A1 (0.35) | F2L3MBTL1CSNK2A1CSNK2A2KDM4E | |
| SCHEMBL2497481 | 0.77 | F2 (0.45) | F2HDAC8L3MBTL1ITGB1ITGA4 | |
| SCHEMBL22508149 | 0.76 | F2 (0.34) | F2L3MBTL1CSNK2A1CSNK2A2 | |
| SCHEMBL13280913 | 0.74 | F2 (0.46) | F2L3MBTL1 | |
| SCHEMBL3923511 | 0.74 | F2 (0.42) | F2HDAC8NR1I2L3MBTL1ITGB1 | |
| SCHEMBL2494883 | 0.74 | LMNA (0.43) | F2 | |
| SCHEMBL10704446 | 0.73 | F2 (0.39) | F2HDAC8NR1I2L3MBTL1ITGB1 | |
| SCHEMBL6636248 | 0.73 | F2 (0.47) | F2NR1I2L3MBTL1 | |
| SCHEMBL22508201 | 0.72 | F2 (0.36) | F2L3MBTL1CSNK2A1 | |
| SCHEMBL12218423 | 0.72 | F2 (0.39) | F2HDAC8ITGB1ITGA4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | MLKL, CMKLR1, PCSK9 | F2 3631/4885HDAC8 1641/4885NR1I2 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.